Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients

Figure 2

(a) The transient decrease in PSA levels in two CRPC patients (60202 and 91760) who had minor responses. (b) A partial responder (60163) with the PSA levels declining by >50% within 6 months of completing therapy. (c) PostIT PSA levels in two nonresponding patients (FG00594 and FG00566) compared to their preIT baseline levels.

(a)

(b)

(c)